Trial reportSurgical endoscopy2026
Effects of sugammadex on the incidence of postoperative nausea and vomiting in patients undergoing laparoscopic abdominal surgery: a randomized controlled study.
Trial report in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThis study aimed to evaluate whether sugammadex reduces the incidence of postoperative nausea and vomiting (PONV) compared to neostigmine in patients undergoing laparoscopic abdominal surgery under a standardized anesthetic and antiemetic regimen.
methodsIn this randomized controlled trial, 114 adult patients scheduled for elective laparoscopic abdominal surgery were randomly assigned to receive either sugammadex or neostigmine for neuromuscular blockade reversal. All patients received standardized multimodal PONV prophylaxis, including dexamethasone, palonosetron, and acetaminophen. In addition, fentanyl-based intravenous patient-controlled analgesia was administered for postoperative pain control. The primary outcome was the incidence of PONV within 48 h after surgery. Secondary outcomes included PONV severity, analgesic use, and length of hospital stay.
resultsA total of 109 patients were included in the final analysis. The overall incidence of PONV within 48 h did not differ significantly between the sugammadex and neostigmine groups (23.6% vs. 35.2%, P = 0.186). On postoperative day 1, a significantly lower incidence of PONV was observed in the sugammadex group compared to the neostigmine group (5.5% vs. 24.1%, P = 0.006). Other variables showed no significant differences.
conclusionSugammadex did not significantly reduce the overall incidence of PONV within 48 h after surgery. However, a significant reduction in PONV was observed on postoperative day 1, suggesting a potential benefit in early postoperative period. In clinical settings where multimodal prophylaxis is routinely applied, the additional antiemetic benefit of sugammadex may be limited. Further studies are warranted to identify patient subgroups that may derive greater benefit from sugammadex in terms of PONV reduction.
trial registrationRegistry: Clinical Research Information Service. Number: KCT0008895. Date: 27 October, 2023.
Indexed as
Identifiers
41071214What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.